Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Xinxiang, Henan, China

    Main Sales Markets: North America,Eastern Europe,Asia,Middle East,Africa

  • Monthly Production Capacity: 30000000

    Contract Manufacturing: CRO,CMO

    Packaging Information: vials or syringe

  • Delivery Lead Time: 1 month

    Sample Provided: yes

    Payment Terms: T/T

    Influenza Vaccine 2022

    [Vaccination Subjects]

    The vaccine is approved for use in people aged 3 and above, especially in vulnerable people and high risk population for influenza complications, such as children, the elderly, the weak and people in influenza epidemic areas.

    [Active ingredients] Hemagglutinin of prevalent strains of influenza virus in 2022-2023 northern and southern hemisphere influenza season. 

    an A/Victoria/2570/2019 (H1N1)pdm09-like virus;

    an A/Darwin/9/2021 (H3N2)-like virus;

    a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

    a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

    [Excipients] Na2HPO4, NaH2PO4, NaCl.  [Specifications] 0.5ml per vial (syringe), 0.5ml human dose for each use, contains 15µg HA of each type of influenza strains.

Send your message to this supplier
  • From:
  • To:
    Hualan Biological Vaccine Inc.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service